Employees: 1,462
Size Shofu (7979.T) is a Japan Health Care company (Medical Specialties) with a market value of $510M, the 1064th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥2,272 on 18 Nov 2026.
Performance Over six months the shares gained 31.9%, against -19.1% for the median peer and -1.4% for the Japan market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue grew 8.7% over the last twelve months (peer median +6.3%); the operating margin is 13.8% (peer median 2.2%).
Valuation It trades at 13.2× forward earnings against a peer median of 23.0× (2nd cheapest of 9).
Capital Return on invested capital runs 4.5 points above its cost of capital (5.6% WACC).
Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥42.3B | ¥40.0B | ¥38.7B | ¥35.1B | ¥31.7B |
| Revenue growth | — | +3% | +10% | +11% | — |
| Gross profit | ¥25.1B | ¥23.7B | ¥23.0B | ¥21.0B | ¥18.7B |
| EBITDA | ¥7.21B | ¥6.44B | ¥6.45B | ¥5.88B | ¥4.80B |
| Net income | ¥6.23B | ¥4.89B | ¥4.32B | ¥3.66B | ¥3.14B |
| Free cash flow | n/a | -¥62.0M | ¥2.22B | ¥1.47B | ¥1.62B |
| Capital expenditure | n/a | ¥3.60B | ¥1.32B | ¥1.71B | ¥1.63B |
| Total debt | ¥1.24B | ¥257M | ¥213M | ¥457M | ¥1.34B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 7979.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.7% | -5.8% | 4th highest of 21 |
| 6-month return | +31.9% | -19.1% | 5th highest of 21 |
| Distance from 52-week high | -6.1% | -40.9% | 2nd highest of 21 |
| Revenue growth (TTM) | +8.7% | +6.3% | 8th highest of 21 |
| Operating margin | 13.8% | 2.2% | 5th highest of 21 |
| Forward P/E | 13.2× | 23.0× | 2nd cheapest of 9 |
| ROIC minus cost of capital | +4.5 pp | -2.2 pp | 3rd highest of 18 |
| EV / EBITDA | 9.6× | n/a | — |
| Net debt / EBITDA | -1.7× | -2.1× | 3rd most indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shofu 7979.T | Japan | $510M | +32% | +9% | 14% | 13.2× | n/a | n/a |
| Guangdong Hybribio Biotech 300639.SZ | China | $511M | -18% | -7% | 4% | 57.3× | 0.4% | -13.2% |
| Anteris Technologies Global AVR | United States | $508M | -40% | +9% | -4,880% | n/a | n/a | n/a |
| Assure Tech (Hangzhou) 688075.SS | China | $508M | -27% | -9% | -8% | n/a | 30.8% | -18.6% |
| Anbio Biotechnology NNNN | United States | $518M | -89% | +10% | 67% | n/a | n/a | n/a |
| MedicalSystem Biotechnology 300439.SZ | China | $518M | -9% | +14% | 2% | n/a | 6.0% | -7.7% |
| Zhejiang Orient Gene Biotech 688298.SS | China | $500M | -27% | +18% | -60% | n/a | n/a | n/a |
| Nanjing Vishee Medical Technology 688580.SS | China | $499M | -43% | +7% | 24% | 19.7× | 20.1% | +4.2% |
| medmix MEDX.SW | Switzerland | $494M | +11% | -7% | 6% | 19.4× | 4.5% | +5.0% |
| AVITA Medical RCEL | United States | $529M | +290% | +17% | -34% | n/a | n/a | n/a |
| Myriad Genetics MYGN | United States | $530M | +45% | -3% | -13% | n/a | n/a | n/a |
| Zhejiang Starry Pharmaceutical 603520.SS | China | $491M | -44% | +9% | 3% | 25.8× | n/a | n/a |
| Jin Medical International ZJYL | United States | $532M | +47% | -14% | 2% | n/a | n/a | n/a |
| Wuhan Easy Diagnosis Biomedicine 002932.SZ | China | $485M | -14% | -9% | -51% | n/a | n/a | n/a |
| Hangzhou Alltest Biotech 688606.SS | China | $484M | -20% | 0% | 13% | 6.9× | -6.5% | -4.3% |
| Medprin Regenerative Medical Technologies 301033.SZ | China | $482M | -14% | +23% | 31% | 22.4× | 4.3% | +24.4% |
| Zhejiang Gongdong Medical Technology 605369.SS | China | $542M | -21% | +6% | 9% | 23.5× | 10.2% | +6.5% |
| Guangdong Biolight Meditech 300246.SZ | China | $478M | -35% | +7% | -8% | n/a | 55.3% | -4.7% |
| CellaVision CEVI.ST | Sweden | $477M | +64% | +2% | 23% | 32.6× | 7.1% | +10.0% |
| Contec Medical Systems 300869.SZ | China | $547M | -26% | -2% | -16% | n/a | 15.0% | -19.8% |
| AngioDynamics ANGO | United States | $476M | -4% | +8% | -6% | n/a | n/a | n/a |